maccura(SZ:300463)2021-04-27 16:00Financial Performance - The company's revenue for Q1 2021 reached ¥1,069,535,881.25, representing a 106.14% increase compared to ¥518,832,353.21 in the same period last year[10] - Net profit attributable to shareholders was ¥313,335,250.80, a significant increase of 314.80% from ¥75,538,510.35 in the previous year[10] - The net profit after deducting non-recurring gains and losses was ¥310,711,565.81, up 298.37% from ¥77,995,048.19 year-on-year[10] - The basic earnings per share rose to ¥0.5643, reflecting a 313.10% increase compared to ¥0.1366 in the same quarter last year[10] - The company's operating revenue for Q1 2021 reached 1,069.54 million CNY, a year-on-year increase of 106.14%[25] - Net profit attributable to shareholders for Q1 2021 was 313.34 million CNY, up 314.80% compared to the same period last year[28] - The company reported a net profit of ¥2,090,483,609.45 for the period, up from ¥1,830,654,469.49, reflecting a growth of approximately 14.2%[90] - The total profit for the current period was ¥391,325,457.32, compared to ¥93,811,940.17 in the previous period, which is an increase of around 317.5%[98] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,630,517,914.16, an increase of 4.17% from ¥6,364,982,648.45 at the end of the previous year[10] - The total liabilities as of March 31, 2021, were CNY 3,188,859,307.22, compared to CNY 3,025,211,868.91 at the end of 2020, showing an increase of approximately 5.41%[74] - The total assets of the company as of March 31, 2021, amounted to ¥5,511,475,460.13, compared to ¥5,154,352,698.31 at the end of December 2020, indicating an increase of about 6.9%[90] - The total liabilities increased to ¥2,096,168,655.03 from ¥1,942,167,193.04, reflecting a rise of approximately 7.9%[90] - The company reported a short-term loan of CNY 973,832,110.05, which increased from CNY 921,547,655.36, reflecting a rise of about 5.67%[76] Cash Flow - The net cash flow from operating activities was ¥86,679,373.91, which is a 21.00% increase from ¥71,637,790.83 in the same period last year[10] - Cash inflow from operating activities totaled CNY 1,015,206,612.88, up from CNY 687,761,691.21 year-over-year[110] - Cash outflow for purchasing goods and services was CNY 569,055,767.80, an increase from CNY 406,506,851.18[114] - Cash inflow from financing activities was CNY 379,059,665.73, compared to CNY 326,993,526.16 in the previous period[116] - The company reported a net increase in cash and cash equivalents of CNY -48,433,450.16, compared to CNY 242,221.32 in the previous period[116] Research and Development - The company's R&D investment in Q1 2021 was 50.96 million CNY, a year-on-year increase of 26.89%[30] - The company is actively engaging in research and development of new products and technologies, focusing on the development of chemiluminescence immunoassay instruments and related products[69] - Research and development expenses increased to ¥39,826,443.24 from ¥25,311,159.91, marking a rise of about 57.5%[1] Shareholder and Investment Activities - The company plans to raise funds through a private placement of shares, which has been approved by the China Securities Regulatory Commission[36] - The company has committed to invest RMB 50 million in the Chengdu Biocity Puhua Maike Industrial Investment Fund, representing 5% of the fund's total size of RMB 1.5 billion[42] - The company has approved a share repurchase plan with a total amount not less than RMB 150 million and not exceeding RMB 300 million, with a maximum repurchase price of RMB 60.00 per share[46] - The company is focused on strategic investments and partnerships to drive growth and market expansion in the biotechnology sector[42] Market and Sales Performance - The sales revenue from self-developed products reached 682.12 million CNY, a year-on-year increase of 278.14%[28] - The company experienced a slight overachievement in sales revenue from COVID-19 testing products due to increased demand around the Spring Festival[34] - Sales of the company's self-developed routine products have shown a recovery growth, supported by ongoing market promotion and brand influence[32] Compliance and Governance - The company has made commitments to compensate investors for any losses caused by false statements or omissions in the prospectus during the IPO[56] - The company has adhered to the share lock-up commitment for 12 months from the date of the IPO for its directors and senior management[59] - The company is actively managing its share repurchase strategy in accordance with market conditions and regulatory requirements[48]